@article{e8bde7295d5545dab5f505353ad60213,
title = "Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia",
abstract = "To assess volume loss and flortaucipir uptake in patients with semantic dementia (SD) over time. Eight SD patients (3 female) underwent clinical evaluations, flortaucipir positron emission tomography, and brain magnetic resonance imaging at 2 visits. Voxel-level comparisons of magnetic resonance imaging gray and white matter volume loss and flortaucipir positron emission tomography uptake were performed in SPM12, comparing SD patients to controls at each visit. T-tests on difference images and paired t-tests of flortaucipir uptake were also performed. At the voxel level, SD patients showed asymmetric, bilateral gray volume loss in the temporal lobes, which, via visual inspection, extended posteriorly at follow-up. White matter loss and flortaucipir uptake were noted in SD patients in the left temporal lobe only, which appeared to extend posteriorly, without involvement of the right hemisphere at follow-up. Longitudinal analyses did not support significant changes in flortaucipir uptake between visits. The biological mechanisms of flortaucipir signal in suspected underlying TAR-DNA binding protein 43 pathology are unknown. A 1-year interval is not sufficient time to demonstrate significant longitudinal flortaucipir uptake changes in SD.",
keywords = "MRI, PET, Primary progressive aphasia, Semantic dementia, Tau",
author = "Utianski, {Rene L.} and Hugo Botha and Whitwell, {Jennifer L.} and Martin, {Peter R.} and Schwarz, {Christopher G.} and Duffy, {Joseph R.} and Clark, {Heather M.} and Spychalla, {Anthony J.} and Senjem, {Matthew L.} and Petersen, {Ronald C.} and Knopman, {David S.} and Jack, {Clifford R.} and Lowe, {Val J.} and Josephs, {Keith A.}",
note = "Funding Information: Funding: This study was supported by the National Institutes of Health grants R21 NS94684 (Josephs) and U01 AG006786 (Petersen) and support from the Elsie and Marvin Dekelboum Family Foundation. Funding Information: The authors thank AVID Radiopharmaceuticals, Inc. for their support in supplying [18F]AV-1451 precursor, chemistry production advice and oversight, and FDA regulatory cross-filing permission and documentation needed for this work. Funding: This study was supported by the National Institutes of Health grants R21 NS94684 (Josephs) and U01 AG006786 (Petersen) and support from the Elsie and Marvin Dekelboum Family Foundation. Funding Information: All authors receive research support from the National Institutes of Health (NIH). Dr. Jack consults for Lily and serves on an independent data monitoring board for Roche, but he receives no personal compensation from any commercial entity; he receives research support from the NIH and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Lowe serves on scientific advisory boards for Bayer Schering Pharma, Piramal Life Sciences and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, and the NIH (NIA, NCI). Matthew L. Senjem owns or has owned stock and/or stock options of the following medical-related companies, unrelated to the current work, within past 3 years: Align Technology, Inc., CRISPR Therapeutics, Gilead Sciences, Inc., Globus Medical Inc., Inovio Biomedical Corp., Ionis Pharmaceuticals, Johnson & Johnson, LHC Group, Inc., Medtronic, Inc., Mesa Laboratories, Inc., Natus Medical Incorporated, Parexel International Corporation, and Varex Imaging Corporation. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",
year = "2020",
month = aug,
doi = "10.1016/j.neurobiolaging.2020.04.010",
language = "English (US)",
volume = "92",
pages = "135--140",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
}